

# **Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer**

**Nymox Pharma {NASDAQ: NYMX}** reports results of prospective cross-over study for prostate cancer treatment.

The trial of fexapotide trifluate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls.

## **Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer**

2015-10-29 10:31 ET – News Release

HASBROUCK HEIGHTS, N.J., - **Nymox Pharmaceutical Corp. {NASDAQ: NYMX}** reported today that long-term randomized cross-over data from the Company's trial of fexapotide trifluate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls. The study results indicate that randomized control subjects who subsequently switched to fexapotide had long-term outcomes significantly superior to control patients who did not change (cross-over) to fexapotide treatment.

These results are the initial 18 month follow-up results for

the fexapotide trial for prostate cancer to be reported. The cross-over study arm of NX03-0040 consisted of 35 subjects. Based on biopsy progression the proportion of patients who progressed on biopsy and required biopsy progression-related surgery or radiotherapy in the cross-over group (0%) at 18 months was significantly less than in the control group ( $p<.03$ ).

The cross-over group patients received randomized fexapotide 15 mg or 2.5 mg in a single treatment targeted toward the positive baseline cancer focus identified in initial positive biopsies. There were no cases in either of the 2 fexapotide dosage level treatment groups with biopsy progression at 18 months ( $p<.03$ ).

In addition to the positive clinical progression results, the primary endpoint of the study (re-biopsy absence of tumor in the initially positive biopsy baseline area of the prostate) also reached statistical significance ( $p<.03$ ) in the cross-over study. At the 18 month assessments, the post-treatment biopsy taken from the treated area of the prostate which was initially positive at baseline, showed absence of tumor (tumor presence in re-biopsy of baseline positive focus  $n=0$ ) in the cross-over treated patients, which was statistically significant compared to controls ( $p<.03$ ).

The Company expects to report results from its long-term NX03-0040 low grade localized prostate cancer study in the fourth quarter.

One of the major problems with current prostate treatments for

localized prostate cancer (radical prostatectomy, external beam radiation, or brachytherapy) is the relatively high incidence of reported sexual dysfunction post-treatment. In 9 studies, NX-1207 treatment has been shown to have no significant adverse effect post-treatment on sexual function or testosterone levels.

**For more information please contact [info@nymox.com](mailto:info@nymox.com)**

## Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of

the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2014, and its Quarterly Reports.



**Contact:**  
**Paul Averbach**  
**Nymox Pharmaceutical Corporation**

**[www.nymox.com](http://www.nymox.com)**

© 2015 Canjex Publishing Ltd. All rights reserved.